Drug intelligence / Profile preview

BIND-014

Development stage: Phase 2
Lead developer: Pfizer
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

BIND-014 is a prostate-specific membrane antigen (PSMA)-targeted Accurin (polymeric nanoparticle) containing docetaxel. It has a diameter of approximately 100nm and is designed to improve the therapeutic index of docetaxel by increasing its intratumoral concentration and duration of exposure. The nanoparticle consists of docetaxel encapsulated in polylactic acid with a hydrophilic polyethylene glycol (PEG) corona decorated with small-molecule PSMA-targeting ligands. BIND-014 allows gradual release of docetaxel upon degradation of the polylactic acid, while the PEG encapsulation helps escape the host immune response.

Other names: PSMA-targeted docetaxel nanoparticles

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on BIND-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIND-014.

Explore the full profile